Table 1.
Participant characteristics
| Characteristics | Healthy controls (N = 61) | Glioma patients (N = 84) | p |
|---|---|---|---|
| Age (mean (SD)) | 48.03 (9.62) | 45.68 (15.23) | 0.115 |
| Sex (number of females (males)) | 27 (34) | 23 (61) | 0.053 |
| Tumor WHO grade (II/III/IV) | NA | 37/17/30 | |
| Tumor histology (GBM/A/O/NA) | NA | 30/30/23/1 | |
| Tumor volume, corrected for headsize (mean ml (SD)) | NA | 39.8 (38.0) | |
| Tumor side (left/right/bilateral) | NA | 49/31/4 | |
| IDH-mutant, 1p/19q non-codeleted glioma (number (%)) | NA | 28 (33.3) | |
| IDH-mutant, 1p/19q-codeleted glioma (number (%)) | NA | 17 (20.2) | |
| IDH-wildtype glioblastoma (number (%)) | NA | 30 (35.7) | |
| Unknown molecular subtype (number (%)) | NA | 9 (10.7) | |
| Epilepsy (yes (no)) | NA | 70 (14) | |
| KPS (median (range) / NA) | NA | 100 (50—100) / 11 |
Tumor histology is based on the 2007 and 2021 WHO classification of human brain tumors [25, 38]. IDH-mutation status and codeletion status were identified using the 2021 WHO classification and extrapolated for the subjects recruited before 2016.
SD Standard Deviation, GBM Glioblastoma, A Astrocytoma, O Oligodendroglioma, NA Not available